{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA1-Associated+Protein-1+%28BAP1%29+Mutations",
    "query": {
      "condition": "BRCA1-Associated Protein-1 (BAP1) Mutations"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:10:43.967Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05960773",
      "title": "Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Malignant Mesothelioma (MM)",
        "Early-stage Mesothelioma",
        "Subclinical Mesothelioma",
        "BRCA1-Associated Protein-1 (BAP1) Mutations",
        "Early-stage BAP1-associated Malignancies"
      ],
      "interventions": [
        {
          "name": "Decitabine/cedazuridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 9,
      "start_date": "2024-01-31",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-22T03:10:43.967Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05960773"
    },
    {
      "nct_id": "NCT06654050",
      "title": "Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Malignant Mesothelioma (MM)",
        "Early-stage Mesothelioma",
        "Subclinical Mesothelioma",
        "BRCA1-Associated Protein-1 (BAP1) Mutations",
        "Early-stage BAP1-associated Malignancies"
      ],
      "interventions": [
        {
          "name": "alrizomadlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-03-16",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T03:10:43.967Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06654050"
    },
    {
      "nct_id": "NCT04431024",
      "title": "Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Familial Cancer",
        "BRCA1-Associated Protein-1 (BAP1) Mutations",
        "Tumor Predisposition Syndrome (TPDS)",
        "Mesothelioma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "30 Years to 120 Years"
      },
      "enrollment_count": 800,
      "start_date": "2021-03-30",
      "completion_date": "2038-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-22T03:10:43.967Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04431024"
    }
  ]
}